glp 1 oral liquid EllieMD GLP-1 Oral Liquid Therapy for
Description
Robinson et al
Given the role of GLP-1RAs and other incretin-based medications widely used for the treatment of T2D and obesity, surprisingly little research has been directed at a comprehensive assessment of even the most frequent GI adverse events (125)
These agents require careful dose titrations due to their adverse drug event (ADE) profile, which commonly includes nausea and vomiting
Importantly, confirmed acute pancreatitis is a reason to discontinue therapy per FDA prescribing information
Pay attention to details about coverage levels and any specific requirements or restrictions
Haemoglobin A1C (HbA1c) Glycosylated Hemoglobin Average Blood Glucose Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) Index Test 2
